NanoSphere Health Sciences Inc. (NSHS.CN)
CAD 0.09
(70.0%)
CAD 0.09
(70.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 17.97 Thousand USD | -70.07% |
| 2022 | 60.04 Thousand USD | -54.68% |
| 2021 | 132.51 Thousand USD | 140.11% |
| 2020 | 55.18 Thousand USD | -83.46% |
| 2019 | 333.72 Thousand USD | -74.7% |
| 2018 | 1.31 Million USD | -65.72% |
| 2017 | 3.84 Million USD | 275.93% |
| 2016 | 1.02 Million USD | 463.77% |
| 2015 | 181.58 Thousand USD | 90.36% |
| 2014 | 95.38 Thousand USD | -0.51% |
| 2013 | 95.88 Thousand USD | -98.61% |
| 2012 | 6.87 Million USD | 12.21% |
| 2011 | 6.13 Million USD | 22.61% |
| 2010 | 5 Million USD | 891.13% |
| 2009 | 504.51 Thousand USD | 55.16% |
| 2008 | 325.15 Thousand USD | -95.82% |
| 2007 | 7.77 Million USD | 2564.4% |
| 2006 | 291.86 Thousand USD | -8.49% |
| 2005 | 318.94 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 17.92 Thousand USD | -0.28% |
| 2024 Q2 | 33 Thousand USD | 84.14% |
| 2023 Q3 | 19.02 Thousand USD | -42.93% |
| 2023 Q2 | 33.32 Thousand USD | -14.93% |
| 2023 Q1 | 39.17 Thousand USD | -34.75% |
| 2023 Q4 | 17.97 Thousand USD | -5.51% |
| 2023 FY | 17.97 Thousand USD | -70.07% |
| 2022 Q4 | 60.04 Thousand USD | -7.55% |
| 2022 Q3 | 64.95 Thousand USD | -30.56% |
| 2022 Q1 | 130.26 Thousand USD | -1.7% |
| 2022 Q2 | 93.53 Thousand USD | -28.2% |
| 2022 FY | 60.04 Thousand USD | -54.68% |
| 2021 Q1 | 30.78 Thousand USD | -44.23% |
| 2021 FY | 132.51 Thousand USD | 140.11% |
| 2021 Q3 | 150.95 Thousand USD | 2006.21% |
| 2021 Q4 | 132.51 Thousand USD | -12.21% |
| 2021 Q2 | 7167.00 USD | -76.72% |
| 2020 Q1 | 246.59 Thousand USD | -26.11% |
| 2020 Q4 | 55.18 Thousand USD | -58.18% |
| 2020 Q3 | 131.95 Thousand USD | -19.6% |
| 2020 Q2 | 164.12 Thousand USD | -33.44% |
| 2020 FY | 55.18 Thousand USD | -83.46% |
| 2019 Q2 | 1.74 Million USD | -18.43% |
| 2019 FY | 333.72 Thousand USD | -74.7% |
| 2019 Q1 | 2.13 Million USD | 62.14% |
| 2019 Q4 | 333.72 Thousand USD | -76.95% |
| 2019 Q3 | 1.44 Million USD | -17.01% |
| 2018 Q4 | 1.31 Million USD | -33.38% |
| 2018 Q2 | 2.16 Million USD | -23.8% |
| 2018 Q1 | 2.83 Million USD | -26.32% |
| 2018 Q3 | 1.98 Million USD | -8.34% |
| 2018 FY | 1.31 Million USD | -65.72% |
| 2017 Q1 | 905.74 Thousand USD | -11.52% |
| 2017 Q2 | 774.96 Thousand USD | -14.44% |
| 2017 FY | 3.84 Million USD | 275.93% |
| 2017 Q3 | 1.32 Million USD | 70.87% |
| 2017 Q4 | 3.84 Million USD | 190.62% |
| 2016 FY | 1.02 Million USD | 463.77% |
| 2016 Q3 | 1.09 Million USD | 693.78% |
| 2016 Q4 | 1.02 Million USD | -6.12% |
| 2016 Q1 | 173.23 Thousand USD | -4.6% |
| 2016 Q2 | 137.37 Thousand USD | -20.7% |
| 2015 FY | 181.58 Thousand USD | 90.36% |
| 2015 Q1 | 85.12 Thousand USD | -10.76% |
| 2015 Q2 | 49.82 Thousand USD | -41.46% |
| 2015 Q4 | 181.58 Thousand USD | -4.8% |
| 2015 Q3 | 190.74 Thousand USD | 282.8% |
| 2014 FY | 95.38 Thousand USD | -0.51% |
| 2014 Q1 | 63.26 Thousand USD | -34.01% |
| 2014 Q4 | 95.38 Thousand USD | -25.99% |
| 2014 Q3 | 128.88 Thousand USD | 111.48% |
| 2014 Q2 | 60.94 Thousand USD | -3.67% |
| 2013 FY | 95.88 Thousand USD | -98.61% |
| 2013 Q4 | 95.88 Thousand USD | -92.3% |
| 2013 Q3 | 1.24 Million USD | -22.05% |
| 2013 Q2 | 1.59 Million USD | -74.6% |
| 2013 Q1 | 6.29 Million USD | -8.57% |
| 2012 Q4 | 6.87 Million USD | 75.37% |
| 2012 Q1 | 5.4 Million USD | -11.9% |
| 2012 FY | 6.87 Million USD | 12.21% |
| 2012 Q2 | 4.37 Million USD | -19.05% |
| 2012 Q3 | 3.92 Million USD | -10.28% |
| 2011 Q4 | 6.13 Million USD | -51.04% |
| 2011 FY | 6.13 Million USD | 22.61% |
| 2011 Q3 | 12.52 Million USD | -5.42% |
| 2011 Q2 | 13.23 Million USD | 120.15% |
| 2011 Q1 | 6.01 Million USD | 20.27% |
| 2010 Q2 | 428.7 Thousand USD | -13.06% |
| 2010 FY | 5 Million USD | 891.13% |
| 2010 Q4 | 5 Million USD | 1164.43% |
| 2010 Q1 | 493.13 Thousand USD | -2.26% |
| 2010 Q3 | 395.47 Thousand USD | -7.75% |
| 2009 Q2 | 225.94 Thousand USD | -14.21% |
| 2009 Q4 | 504.51 Thousand USD | 6.3% |
| 2009 FY | 504.51 Thousand USD | 55.16% |
| 2009 Q1 | 263.36 Thousand USD | -19.0% |
| 2009 Q3 | 474.59 Thousand USD | 110.05% |
| 2008 Q1 | 7.03 Million USD | -9.48% |
| 2008 Q4 | 325.15 Thousand USD | -36.94% |
| 2008 Q2 | 7.04 Million USD | 0.09% |
| 2008 Q3 | 515.61 Thousand USD | -92.68% |
| 2008 FY | 325.15 Thousand USD | -95.82% |
| 2007 Q3 | 8.4 Million USD | 2.19% |
| 2007 FY | 7.77 Million USD | 2564.4% |
| 2007 Q4 | 7.77 Million USD | -7.48% |
| 2007 Q2 | 8.22 Million USD | 2184.27% |
| 2007 Q1 | 360.08 Thousand USD | 23.37% |
| 2006 Q4 | 291.86 Thousand USD | -6.29% |
| 2006 Q3 | 311.45 Thousand USD | -1.18% |
| 2006 Q2 | 315.17 Thousand USD | 0.56% |
| 2006 FY | 291.86 Thousand USD | -8.49% |
| 2006 Q1 | 313.43 Thousand USD | -1.73% |
| 2005 Q3 | 349.26 Thousand USD | 0.0% |
| 2005 FY | 318.94 Thousand USD | 0.0% |
| 2005 Q4 | 318.94 Thousand USD | -8.68% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 4.19 Million CAD | 99.571% |
| Asep Medical Holdings Inc | 25.61 Million CAD | 99.93% |
| BetterLife Pharma Inc. | 324.74 Thousand CAD | 94.466% |
| BioVaxys Technology Corp. | 113.47 Thousand CAD | 84.163% |
| ChitogenX Inc. | 534 Thousand CAD | 96.634% |
| Rapid Dose Therapeutics Corp. | 1.88 Million CAD | 99.047% |
| Defence Therapeutics Inc. | 477.74 Thousand CAD | 96.238% |
| Entheon Biomedical Corp. | 401.07 Thousand CAD | 95.519% |
| Gemina Laboratories Ltd. | 1.45 Million CAD | 98.766% |
| Glow Lifetech Corp. | 1.91 Million CAD | 99.061% |
| Lexston Life Sciences Corp. | 750.94 Thousand CAD | 97.607% |
| Pharmala Biotech Holdings Inc. | 2.41 Million CAD | 99.255% |
| Doseology Sciences Inc. | 1.1 Million CAD | 98.369% |
| MYND Life Sciences Inc. | 797.54 Thousand CAD | 97.747% |
| Nova Mentis Life Science Corp. | 31.05 Thousand CAD | 42.136% |
| PharmaTher Holdings Ltd. | 2.58 Million CAD | 99.306% |
| PreveCeutical Medical Inc. | 181.51 Thousand CAD | 90.099% |
| Telescope Innovations Corp. | 3.02 Million CAD | 99.406% |